ZA201803531B - Protein kinase inhibitor, preparation method and medical use thereof - Google Patents

Protein kinase inhibitor, preparation method and medical use thereof

Info

Publication number
ZA201803531B
ZA201803531B ZA2018/03531A ZA201803531A ZA201803531B ZA 201803531 B ZA201803531 B ZA 201803531B ZA 2018/03531 A ZA2018/03531 A ZA 2018/03531A ZA 201803531 A ZA201803531 A ZA 201803531A ZA 201803531 B ZA201803531 B ZA 201803531B
Authority
ZA
South Africa
Prior art keywords
preparation
protein kinase
kinase inhibitor
medical use
medical
Prior art date
Application number
ZA2018/03531A
Other languages
English (en)
Inventor
Lei Yin
Wenjian Liu
Heng Li
Dianxi Zhu
Original Assignee
Ganandlee Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58796287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201803531(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ganandlee Pharmaceuticals filed Critical Ganandlee Pharmaceuticals
Publication of ZA201803531B publication Critical patent/ZA201803531B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
ZA2018/03531A 2015-11-30 2018-05-28 Protein kinase inhibitor, preparation method and medical use thereof ZA201803531B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510856641.1A CN106810536A (zh) 2015-11-30 2015-11-30 一种蛋白激酶抑制剂及其制备方法和医药用途
PCT/CN2016/107455 WO2017092635A1 (zh) 2015-11-30 2016-11-28 一种蛋白激酶抑制剂及其制备方法和医药用途

Publications (1)

Publication Number Publication Date
ZA201803531B true ZA201803531B (en) 2021-10-27

Family

ID=58796287

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2018/03531A ZA201803531B (en) 2015-11-30 2018-05-28 Protein kinase inhibitor, preparation method and medical use thereof

Country Status (21)

Country Link
US (2) US11091476B2 (https=)
EP (1) EP3385262B1 (https=)
JP (2) JP6921101B2 (https=)
KR (1) KR20180083421A (https=)
CN (3) CN106810536A (https=)
AU (1) AU2016365366B2 (https=)
BR (1) BR112018010879A2 (https=)
CA (1) CA3002884A1 (https=)
CO (1) CO2018005854A2 (https=)
DK (1) DK3385262T3 (https=)
ES (1) ES2928169T3 (https=)
HU (1) HUE060152T2 (https=)
IL (1) IL259711B (https=)
MA (1) MA42341B2 (https=)
MX (1) MX387207B (https=)
PH (1) PH12018550049A1 (https=)
PT (1) PT3385262T (https=)
RU (1) RU2749437C2 (https=)
UA (1) UA124001C2 (https=)
WO (1) WO2017092635A1 (https=)
ZA (1) ZA201803531B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810536A (zh) * 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN111386272B (zh) 2017-10-27 2023-01-06 费森尤斯卡比肿瘤学有限公司 一种改进的瑞博西尼及其盐的制备方法
JP2021514359A (ja) 2018-02-15 2021-06-10 ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． キナーゼ阻害剤としての複素環式化合物
WO2019170055A1 (zh) * 2018-03-05 2019-09-12 上海海和药物研究开发有限公司 具有cdk4/6激酶抑制活性的化合物、其药用组合物和用途
US20220079944A1 (en) * 2019-01-29 2022-03-17 Beta Pharma, Inc. 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases
WO2020253865A1 (zh) 2019-06-21 2020-12-24 甘李药业股份有限公司 Cdk4/6抑制剂、及其盐和中间体的制备方法
AR119184A1 (es) * 2019-06-21 2021-12-01 Gan & Lee Pharmaceuticals Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas
WO2022042738A1 (zh) * 2020-08-31 2022-03-03 甘李药业股份有限公司 一种含cdk4/6抑制剂的药物组合物
US11685744B2 (en) * 2020-09-21 2023-06-27 Prelude Therapeutics Incorporated CDK inhibitors and their use as pharmaceuticals
CA3205652A1 (en) 2020-12-18 2022-06-23 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals
CN112390793B (zh) * 2021-01-19 2021-04-27 中国药科大学 Cdk6/dyrk2双靶点抑制剂及其制备方法和应用
WO2022218247A1 (zh) * 2021-04-12 2022-10-20 甘李药业股份有限公司 作为cdk4/6抑制剂的氘代化合物
US20250332167A1 (en) * 2021-05-17 2025-10-30 Gan & Lee Pharmaceuticals Co., Ltd. Pharmaceutical use of cdk 4/6 inhibitor
CN118119393A (zh) * 2021-09-14 2024-05-31 甘李药业股份有限公司 一种cdk4/6抑制剂的医药用途
WO2023116862A1 (zh) * 2021-12-24 2023-06-29 江苏恒瑞医药股份有限公司 氢化吲哚类化合物、其制备方法及其在医药上的应用
CN115093397B (zh) * 2022-06-07 2023-09-05 自贡市第三人民医院 一种用于治疗肿瘤的化合物、合成方法及应用
WO2024051717A1 (zh) * 2022-09-08 2024-03-14 上海深势唯思科技有限责任公司 作为plk1抑制剂的化合物及其制备方法和用途
CN119790049A (zh) * 2022-09-30 2025-04-08 楚浦创制（武汉）医药科技有限公司 2-氨基嘧啶类化合物及其应用、药用组合物
CN121270553A (zh) * 2025-10-31 2026-01-06 广西医科大学第二附属医院(广西医科大学第二临床医学院) 一种抗肿瘤化合物、抗肿瘤制剂及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
KR20020084116A (ko) 2000-02-07 2002-11-04 애보트 게엠베하 운트 콤파니 카게 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도
MXPA04005939A (es) 2002-01-22 2005-01-25 Warner Lambert Co 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
US20070117818A1 (en) 2004-02-04 2007-05-24 Masaichi Hasegawa Pyrimidinone compounds useful as kinase inhibitors
KR20080110998A (ko) 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Ｊａｋ­２ 조절자로서 ４­아릴­２­아미노­피리미딘 또는 4­아릴­２­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
WO2008124085A2 (en) * 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
HUE030912T2 (en) 2008-02-15 2017-06-28 Rigel Pharmaceuticals Inc Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
BRPI0912564A2 (pt) 2008-05-16 2019-09-24 F. Hoffman-La Roche Ag inibidores de jnk
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2013173506A2 (en) * 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
EP2909194A1 (en) * 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN106608879A (zh) 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN106810536A (zh) * 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
EP3679043B9 (en) 2017-09-05 2023-09-27 Neumora Therapeutics, Inc. Vasopressin receptor antagonists and products and methods related thereto
WO2022218247A1 (zh) 2021-04-12 2022-10-20 甘李药业股份有限公司 作为cdk4/6抑制剂的氘代化合物

Also Published As

Publication number Publication date
MX387207B (es) 2025-03-18
RU2749437C2 (ru) 2021-06-10
MX2018006370A (es) 2018-09-24
PH12018550049A1 (en) 2018-10-29
CN108290864B (zh) 2022-05-10
CN113956238B (zh) 2023-07-14
CN113956238A (zh) 2022-01-21
IL259711A (en) 2018-07-31
US20210371418A1 (en) 2021-12-02
US20200165239A1 (en) 2020-05-28
MA42341B2 (fr) 2021-05-31
CA3002884A1 (en) 2017-06-08
RU2018122864A3 (https=) 2020-03-17
AU2016365366B2 (en) 2021-03-04
ES2928169T3 (es) 2022-11-15
EP3385262A1 (en) 2018-10-10
HUE060152T2 (hu) 2023-02-28
MA42341A1 (fr) 2018-06-29
CO2018005854A2 (es) 2018-06-20
US11787801B2 (en) 2023-10-17
UA124001C2 (uk) 2021-07-07
CN106810536A (zh) 2017-06-09
BR112018010879A2 (pt) 2018-11-21
JP2019500413A (ja) 2019-01-10
IL259711B (en) 2022-08-01
PT3385262T (pt) 2022-10-18
RU2018122864A (ru) 2020-01-13
DK3385262T3 (da) 2022-10-10
CN108290864A (zh) 2018-07-17
EP3385262A4 (en) 2019-06-19
JP6921101B2 (ja) 2021-08-18
JP2021138737A (ja) 2021-09-16
AU2016365366A1 (en) 2018-05-17
KR20180083421A (ko) 2018-07-20
EP3385262B1 (en) 2022-07-13
WO2017092635A1 (zh) 2017-06-08
US11091476B2 (en) 2021-08-17

Similar Documents

Publication Publication Date Title
IL259711A (en) Methods for the preparation of protein kinase inhibitors and their medical use
PT3546457T (pt) Derivado de pirazolo-heteroarílico, método de preparação e a utilização médica do mesmo
IL289766A (en) tfpi inhibitory antibodies and their uses
HUE057289T2 (hu) Oxopikolinamid-származék, annak elõállítási módszere és gyógyszerészeti felhasználása
EP3244727A4 (en) Insecticidal proteins and methods for their use
PT3222647T (pt) Poliésteres, processo para a sua produção e a sua utilização
ZA201806436B (en) Insecticidal proteins and methods for their use
PT3205650T (pt) Inibidor de egfr, e preparação e aplicação do mesmo
PT3388420T (pt) Compostos de quinolina, método de preparação dos mesmos e uso dos mesmo como fármaco inibidor do transportador de urato
EP3259003A4 (en) Patient interface and aspects thereof
PT3297641T (pt) Métodos de armazenamento de sangue total e respetivas composições
ZA201700021B (en) Alk kinase inhibitor, and preparation method and use thereof
PL3373910T3 (pl) Preparat echinomycyny, sposób wytwarzania i sposób stosowania
IL262929A (en) Composition, and application and pharmaceutical preparation thereof
PL3398598T3 (pl) Pochodne sulfonoamidowe oraz sposoby ich wytwarzania i zastosowanie
SG11201802754XA (en) Blood preparation and profiling
ZA201802141B (en) Egfr kinase inhibitor and preparation method and use thereof
ZA201704743B (en) Mangiferin-6-o-berberine salt and preparation method and use thereof
ZA201801134B (en) Hydroxytriazine compound and medical use thereof
PT3350150T (pt) 1,1-difeniletilenos substituídos por alcenilfenoxilo, processos para a sua preparação e sua utilização
EP3530738A4 (en) TNF-ALPHA BINDING APTAMER, AND THERAPEUTIC USE
ZA201708339B (en) Primin derivatives, method of preparation thereof and use thereof
AU2015904075A0 (en) Blood preparation and profiling
IL251930A0 (en) Anylhydroxy derivatives, their preparation and medical uses
GB201504785D0 (en) Foodstuff, Use and Method